Funding for this research was provided by:
National Institutes of Health (F30AG043282, UL1TR002373, F30CA210912)
National Institute of General Medical Sciences (T32GM008692)
Received: 3 January 2019
Accepted: 17 March 2019
First Online: 27 March 2019
Ethics approval and consent to participate
: As determined by consultation with the University of Wisconsin–Madison Institutional Review Board (IRB) and via a certification tool prior to conducting the survey, the survey was found to be exempt from a full review by the IRB due to the program evaluation and quality improvement nature of this project.
: As part of a quality improvement project for this course, we did not ask for informed consent for publication from survey participants. However, the identity of survey respondents was maintained as anonymous via a neutral broker. Additionally, the survey as a whole and individual questions were optional for participants.
: The authors declare that they have no competing interests. M.E.B. declares the following: Medical advisory board of Strata Oncology; Research funding from Abbvie, Genetech, Puma, and Loxo Oncology.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.